Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E.

J Immunother Cancer. 2019 Feb 4;7(1):29. doi: 10.1186/s40425-019-0498-z.

2.

Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells.

Bach AS, Derocq D, Laurent-Matha V, Montcourrier P, Sebti S, Orsetti B, Theillet C, Gongora C, Pattingre S, Ibing E, Roger P, Linares LK, Reinheckel T, Meurice G, Kaiser FJ, Gespach C, Liaudet-Coopman E.

Oncotarget. 2015 Sep 29;6(29):28084-103. doi: 10.18632/oncotarget.4394.

3.

Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment.

Laurent-Matha V, Huesgen PF, Masson O, Derocq D, Prébois C, Gary-Bobo M, Lecaille F, Rebière B, Meurice G, Oréar C, Hollingsworth RE, Abrahamson M, Lalmanach G, Overall CM, Liaudet-Coopman E.

FASEB J. 2012 Dec;26(12):5172-81. doi: 10.1096/fj.12-205229. Epub 2012 Aug 16.

4.

Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis.

Derocq D, Prébois C, Beaujouin M, Laurent-Matha V, Pattingre S, Smith GK, Liaudet-Coopman E.

Oncogene. 2012 Jun 28;31(26):3202-12. doi: 10.1038/onc.2011.501. Epub 2011 Nov 14.

5.

Cathepsin-D, a key protease in breast cancer, is up-regulated in obese mouse and human adipose tissue, and controls adipogenesis.

Masson O, Prébois C, Derocq D, Meulle A, Dray C, Daviaud D, Quilliot D, Valet P, Muller C, Liaudet-Coopman E.

PLoS One. 2011 Feb 2;6(2):e16452. doi: 10.1371/journal.pone.0016452.

6.

Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth.

Beaujouin M, Prébois C, Derocq D, Laurent-Matha V, Masson O, Pattingre S, Coopman P, Bettache N, Grossfield J, Hollingsworth RE, Zhang H, Yao Z, Hyman BT, van der Geer P, Smith GK, Liaudet-Coopman E.

J Cell Sci. 2010 Oct 1;123(Pt 19):3336-46. doi: 10.1242/jcs.070938. Epub 2010 Sep 7.

7.

Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity?

Masson O, Bach AS, Derocq D, Prébois C, Laurent-Matha V, Pattingre S, Liaudet-Coopman E.

Biochimie. 2010 Nov;92(11):1635-43. doi: 10.1016/j.biochi.2010.05.009. Epub 2010 May 21. Review.

8.

Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells.

Nirdé P, Derocq D, Maynadier M, Chambon M, Basile I, Gary-Bobo M, Garcia M.

Oncogene. 2010 Jan 7;29(1):117-27. doi: 10.1038/onc.2009.311. Epub 2009 Oct 5.

9.

Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B.

Laurent-Matha V, Derocq D, Prébois C, Katunuma N, Liaudet-Coopman E.

J Biochem. 2006 Mar;139(3):363-71.

10.

Transcriptional regulation of the human NRIP1/RIP140 gene by estrogen is modulated by dioxin signalling.

Augereau P, Badia E, Fuentes M, Rabenoelina F, Corniou M, Derocq D, Balaguer P, Cavailles V.

Mol Pharmacol. 2006 Apr;69(4):1338-46. Epub 2006 Jan 3.

PMID:
16391242
11.

Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis.

Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, Prébois C, Rochefort H, Vignon F.

Cancer Lett. 2006 Jun 18;237(2):167-79. Epub 2005 Jul 19. Review.

PMID:
16046058
12.

Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells.

Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M.

Oncogene. 2002 Aug 1;21(33):5127-34.

13.

Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview.

Rochefort H, Platet N, Hayashido Y, Derocq D, Lucas A, Cunat S, Garcia M.

J Steroid Biochem Mol Biol. 1998 Apr;65(1-6):163-8. Review.

PMID:
9699869
14.
15.

Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor.

Garcia M, Derocq D, Platet N, Bonnet S, Brouillet JP, Touitou I, Rochefort H.

J Steroid Biochem Mol Biol. 1997 Apr;61(1-2):11-7.

PMID:
9328205
16.

Biological and clinical significance of cathepsin D in breast cancer metastasis.

Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Brouillet JP, Rochefort H.

Stem Cells. 1996 Nov;14(6):642-50. Review.

17.

Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors.

Liaudet E, Derocq D, Rochefort H, Garcia M.

Cell Growth Differ. 1995 Sep;6(9):1045-52.

18.

Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.

Coopman P, Garcia M, Brünner N, Derocq D, Clarke R, Rochefort H.

Int J Cancer. 1994 Jan 15;56(2):295-300.

PMID:
8314314
19.
20.
21.

Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF7 breast cancer cells and mapping on chromosome 11.

Augereau P, Garcia M, Mattei MG, Cavailles V, Depadova F, Derocq D, Capony F, Ferrara P, Rochefort H.

Mol Endocrinol. 1988 Feb;2(2):186-92.

PMID:
3398849
22.

Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

Gill PG, Vignon F, Bardon S, Derocq D, Rochefort H.

Breast Cancer Res Treat. 1987 Oct;10(1):37-45.

PMID:
3689980
23.

Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness.

Garcia M, Lacombe MJ, Duplay H, Cavailles V, Derocq D, Delarue JC, Krebs B, Contesso G, Sancho-Garnier H, Richer G, et al.

J Steroid Biochem. 1987;27(1-3):439-45.

PMID:
3320536
24.

Characterization of monoclonal antibodies to the estrogen-regulated Mr 52,000 glycoprotein and their use in MCF7 cells.

Garcia M, Capony F, Derocq D, Simon D, Pau B, Rochefort H.

Cancer Res. 1985 Feb;45(2):709-16.

25.

The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor.

Bardon S, Vignon F, Derocq D, Rochefort H.

Mol Cell Endocrinol. 1984 May;35(2-3):89-96.

PMID:
6734930
26.

Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.

Vignon F, Lippman ME, Nawata H, Derocq D, Rochefort H.

Cancer Res. 1984 May;44(5):2084-8.

27.

[Estrogen-induced proteins secreted by MCF7 human breast cancer cells stimulate their proliferation].

Vignon F, Derocq D, Chambon M, Rochefort H.

C R Seances Acad Sci III. 1983 Jan 24;296(3):151-6. French.

PMID:
6404517
28.

Effect of estradiol on the ultrastructure of the MCF7 human breast cancer cells in culture.

Vic P, Vignon F, Derocq D, Rochefort H.

Cancer Res. 1982 Feb;42(2):667-73.

29.

Effects of plasma estrogen sulfates in mammary cancer cells.

Vignon F, Terqui M, Westley B, Derocq D, Rochefort H.

Endocrinology. 1980 Apr;106(4):1079-86. No abstract available.

PMID:
6244140

Supplemental Content

Loading ...
Support Center